Coronavirus disease 2019 (COVID-19) in the heart transplant population: a single-centre experience
- 19 October 2020
- journal article
- research article
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 58 (5) , 899-906
Abstract
OBJECTIVES: Few anecdotal cases have been reported in the literature regarding heart transplant recipients and infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We report our experience with 6 patients hospitalized in Northern Italy during the outbreak.METHODS: Of the 396 living heart transplant recipients from 1985 to 2020 included in the study, 6 patients developed the novel 2019 coronavirus disease. Risk factors, last follow-up characteristics, onset presentation, in-hospital course of disease and blood examinations data were collected for these patients.RESULTS: All patients were symptomatic and had positive results from a nasopharyngeal swab test for SARS-CoV-2. Of the 6 patients, 5 were hospitalized and 1 remained self-quarantined at home. Two patients died and 3 were discharged home. Two patients were admittted to the intensive care unit . Immunosuppressive therapy was modified with a median reduction comprising doses that were 50% cyclosporine and 50% mycophenolate. All patients received a medium-dose of corticosteroids as a bolus medication in addition to their therapy. All hospitalized patients received hydroxychloroquine; 2 patients received ritonavir/lopinavir. Broad-spectrum antibiotics for prophylaxis were administered to all. One patient had an ischaemic stroke and died of sepsis.CONCLUSIONS: In the absence of any strong evidence regarding the treatment of heart transplant recipients infected with SARS-CoV-2, we faced a new challenge in managing viral infection in an immunosuppressed population. Because immunomodulation interaction with the infection seems to be crucial for developing severe forms of the disease, we managed to reduce immunosuppressive therapy by adding medium doses of corticosteroids. Despite the limited number of affected patients, this report suggests that special considerations should be given to treating coronavirus disease in the heart transplant recipient population.Keywords
This publication has 23 references indexed in Scilit:
- COVID-19 illness in native and immunosuppressed states: A clinical–therapeutic staging proposalThe Journal of Heart and Lung Transplantation, 2020
- First cases of COVID-19 in heart transplantation from ChinaThe Journal of Heart and Lung Transplantation, 2020
- Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19New England Journal of Medicine, 2020
- Immunosuppression drug‐related and clinical manifestation of Coronavirus disease 2019: a therapeutical hypothesisAmerican Journal of Transplantation, 2020
- Immunosuppression for hyperinflammation in COVID-19: a double-edged sword?The Lancet, 2020
- COVID-19 in kidney transplant recipientsAmerican Journal of Transplantation, 2020
- Management of Critically Ill Adults With COVID-19JAMA, 2020
- Successful recovery of COVID-19 pneumonia in a renal transplant recipient with long-term immunosuppressionAmerican Journal of Transplantation, 2020
- COVID-19: consider cytokine storm syndromes and immunosuppressionThe Lancet, 2020
- Treatment and prevention of cytomegalovirus infection in heart and lung transplantation: an updateExpert Opinion on Pharmacotherapy, 2016